HYUNDAI PHARMACEUTICAL CO., LTD
Financials
Valuation Metrics
HYUNDAI PHARMACEUTICAL CO., LTD's Market Cap is ₩1792B. At end of 2025 it was ₩2726B. Ranked #887 of 2,436 in KR market (top 36%), #472 of 787 on KOSPI (top 60%), #96 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 41%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 179.20B KRW | KR#887/2,436 Sec#96/234 |
| Revenue | 195.16B KRW | KR#1,038/2,436 Sec#63/234 |
| Net Income | 3.92B KRW | KR#1,206/2,436 Sec#83/234 |
| Total Assets | 224.31B KRW | KR#1,208/2,436 Sec#86/234 |
| Net Assets | 134.81B KRW | KR#1,178/2,436 Sec#91/234 |
| Employees | 401 | KR#600/2,436 Sec#51/234 |
| Value | ||
| P/E | 45.70x | KR#1,333/2,436 Sec#86/234 |
| P/B | 1.33x | KR#1,713/2,436 Sec#121/234 |
| P/S | 0.92x | KR#1,334/2,436 Sec#76/234 |
| EV/EBITDA | 29.64x | KR#1,180/2,436 Sec#77/234 |
| FCF Yield | -2.64% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | 2.91% | KR#1,236/2,436 Sec#87/234 |
| ROA | 1.75% | KR#1,181/2,436 Sec#89/234 |
| Op. Margin | 3.64% | KR#1,118/2,436 Sec#85/234 |
| Revenue Growth | 7.82% | KR#1,032/2,436 Sec#96/234 |
| Financial Health | ||
| Debt Ratio | 166.38% | KR#1,390/2,436 Sec#157/234 |
| Total Debt | 49.80B KRW | KR#990/2,436 Sec#67/234 |
| FCF | -4.73B KRW | KR#1,490/2,436 Sec#116/234 |
| Cash | 18.67B KRW | KR#1,279/2,436 Sec#95/234 |
| Current Ratio | 1.28x | KR#1,496/2,436 Sec#159/234 |
| Net Debt/EBITDA | 4.39x | KR#1,050/2,436 Sec#81/234 |
| Dividend | ||
| Div. Yield | 0.56% | KR#1,260/2,436 Sec#79/234 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | 49.33% | KR#242/2,436 Sec#20/234 |
| 1M Return | 8.53% | KR#308/2,436 Sec#21/234 |
| From 52W High | -64.91% | KR#1,950/2,436 Sec#166/234 |
| 1Y MDD | -68.41% | KR#1,876/2,436 Sec#160/234 |
| Trading | ||
| Volume | 819,893 shares | KR#163/2,436 Sec#10/234 |
| Foreign Own. | 3.59% | KR#946/2,436 Sec#91/234 |
| Per Share | ||
| EPS | 131 KRW | KR#1,310/2,436 Sec#92/234 |
| BPS | 4,633 KRW | KR#1,502/2,436 Sec#111/234 |
Company Info
Hyundai Pharmaceutical, established in 1965 and listed on the stock market in 1978, is a pharmaceutical and beverage manufacturing and sales company. It produces and supplies both specialized prescription drugs (such as hypertension treatment Tenormin) and over-the-counter drugs (like alopecia treatment Minoxidil Solution and mosquito bite relief Burmuli) to hospitals, clinics, and pharmacies nationwide. The company is currently conducting Phase 2b clinical trials for HDNO-1605, an innovative new drug for diabetes, and actively seeking improved new drugs to enhance medication adherence in the cardiovascular sector. Hyundai Pharmaceutical is headquartered in Cheonan-si, Chungcheongnam-do.